Date: May 17, 2025

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai- 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Submission of Media Release pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Audited Standalone and Consolidated financial results of the Company for the half year and financial year ended March 31, 2025 duly approved by the Board of Directors of the Company in their meeting held on May 17, 2025.

You are requested to take the same on your record.

Thanking You.
For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2025.05.17 18:47:20 +05'30'

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl.: As above

Media Release

REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE SECOND HALF AND FINANCIAL YEAR ENDED MARCH 31, 2025

May 17, 2025: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the second half and financial year ended March 31, 2025

Consolidated Financial Performance:

FY25 vs FY24

Revenue From Operations	EBITDA	PAT^
FY25: INR 620.36 Cr	**FY25: INR 50.67 Cr**	**FY25: INR 38.42* Cr**
FY24: INR 212.94 Cr	**FY24: INR 31.80 Cr**	**FY24: INR 24.28 Cr**
YoY Growth: 191.33% ↑	*YoY Growth: 59.37%* ↑	*YoY Growth: 58.23%* ↑

^Amount of PAT is before Minority Interest
PAT after Minority Interest **for FY 25 is INR 29.07 Cr*

H2 FY25 vs H1 FY25

Revenue From Operations	EBITDA	PAT^
H2 FY25: INR 347.75 Cr	**H2 FY25: INR 27.15 Cr**	**H2 FY25: INR 20.57* Cr**
H1 FY25: INR 272.61 Cr	**H1 FY25: INR 23.52 Cr**	**H1 FY25: INR 17.85 Cr**
Growth: 27.56% ↑	*Growth: 15.44%* ↑	*Growth: 15.25%* ↑

^Amount of PAT is before Minority Interest
PAT after Minority Interest **for H2 FY25 is INR 16.01 crores*

H2 FY25 vs H2 FY24

Revenue From Operations	EBITDA	PAT^
H2 FY25: INR 347.75 Cr	**H2 FY25: INR 27.15 Cr**	**H2 FY25: INR 20.57* Cr**
H2 FY24: INR 184.90 Cr	**H2 FY24: INR 21.14 Cr**	**H2 FY24: INR 19.01 Cr**
Growth: 88.07% ↑	*Growth: 28.43%* ↑	*Growth: 8.22%* ↑

^Amount of PAT is before Minority Interest
PAT after Minority Interest is **for H2 FY25 is INR 16.01 crores*

H2-FY25 Business Highlights:

- Initiated business in Saudi Arabia and filed Ivermectin 3 mg tablet with strategic partner.
- Commercialized 10+ recently off patented niche products.
- Established strong brand presence with 170 filled and 35+ approved products trademarked globally.
- Started registration in Bosnia and Herzegovina, Kosovo, Mexico, Tanzania, Azerbaijan, Mauritius, Bhutan and Cambodia.
- Own marketing authorization and brands registration started in Chile, Peru, Dominican Republic and El Salvador.

Media Release

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "*The Company has maintained the growth trajectory for the second half of the financial year and has met our expectations. The growth that we have achieved during the financial year testifies the hard work and dedication of our team. Going forward we are looking to expand our reach to new markets and product segments. We are confident that our strong and strategic performance will continue to drive our growth in the future.*"

Financial Statements:

Results for the second half and financial year ended March 31st, 2025, prepared under Ind AS, are available in the Investors section of our website https://remuspharma.com/

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs as well as API (Active Pharmaceutical Ingredient). Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Along with it they are providing technical consultancy services to various distributors for preparation of reports on the dossiers of the products, to be registered by the said distributors in several countries.

Safe Harbor

This document includes certain forward-looking statements which are tentative, based on current expectations of the management of Remus Pharmaceuticals Limited or any of its subsidiaries ("Remus"). These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors, exchange rate fluctuations, cash flow projections, interest, and other costs. Remus, its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Remus does not undertake any obligation to revise or update any forward-looking statement that may be made from time to time by or on behalf of the Company including to reflect actual results, changes in assumptions or changes in factors affecting these statements.

Follow Remus Pharmaceuticals Limited on LinkedIn: https://www.linkedin.com/company/remus-pharmaceuticals/

Contact Information:

Investor Relations Representative: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	**Chief Financial Officer** Ms. Anjali Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com